title: Paraneoplastic Itch Management.
abstract: Paraneoplastic itch occurs as the result of a systemic reaction to an underlying malignancy. Paraneoplastic itch is most commonly associated with lymphoproliferative malignancies and solid tumors that result in cholestasis. Paraneoplastic itch may occur in the absence of a primary rash or in association with dermatologic conditions such as erythroderma, acanthosis nigricans, dermatomyositis, Grover's disease, and eruptive seborrheic keratosis. Treatment of paraneoplastic itch is centered on targeting the underlying malignancy responsible for the systemic reaction. In cases of malignancy that are refractive to treatment, other therapies have been found to be effective for paraneoplastic itch, including selective serotonin reuptake inhibitors, mirtazapine, gabapentin, thalidomide, opioids, aprepitant, and histone deacetylase inhibitors.
authors: Brandon
authors: B
authors: Rowe
authors: Gil
authors: G
authors: Yosipovitch
mesh_terms: D000051:Acantholysis / Q000150:complications / Q000188:drug therapy; D000052:Acanthosis Nigricans / Q000150:complications / Q000188:drug therapy; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D000077608:Aprepitant; D003873:Dermatitis, Exfoliative / Q000150:complications / Q000188:drug therapy; D003882:Dermatomyositis / Q000150:complications / Q000188:drug therapy; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007057:Ichthyosis / Q000150:complications / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017492:Keratosis, Seborrheic / Q000150:complications / Q000188:drug therapy; D008803:Mianserin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000078785:Mirtazapine; D009025:Morpholines / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications / Q000628:therapy*; D064729:Neurokinin-1 Receptor Antagonists / Q000627:therapeutic use; D010257:Paraneoplastic Syndromes / Q000150:complications / Q000188:drug therapy*; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: D000701:Analgesics, Opioid; D000927:Anticonvulsants; D000928:Antidepressive Agents; D000077608:Aprepitant; D056572:Histone Deacetylase Inhibitors; D007166:Immunosuppressive Agents; D008803:Mianserin; D000078785:Mirtazapine; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D013792:Thalidomide